
    
      This trial is a two-arm, multicenter, open labelled, prospective, randomized phase III
      studies. Eligible patients with high-risk locally advanced rectal cancer patients (cT3 with
      any MRF involved, any cT4a/b or lateral node positive) will be randomly assigned, in a 1:1
      ratio, to receive either neoadjuvant mFOLFOXIRI plus bevacizumab with selective radiotherapy
      or induction FOLFOX followed by concomitant chemoradiotherapy.
    
  